Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis. (2021). SKIN The Journal of Cutaneous Medicine, 5(6), s56. https://doi.org/10.25251/skin.5.supp.56